BIO-TECHNOLOGY GENERAL ANNOUNCES LAUNCH OF HUMAN GROWTH HORMONE IN THE UNITED KINGDOM, FRANCE, SPAIN AND DENMARK.General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced its human growth hormone human growth hormone (HGH): see growth hormone. has been launched in The United Kingdom, France, Spain and Denmark by BTG's European licensee, the Ferring Group (Ferring), under the trademark ZomactonTM. BTG's human growth hormone is already marketed by Ferring in Belgium, Germany, Ireland, Luxembourg, The Netherlands and Sweden. It is also approved for marketing in Italy and Portugal, and Ferring is proceeding with plans for launches in those countries. The current European market size for human growth hormone approximates $250 million per annum Per annum Yearly. . Ferring, a Swedish company specializing in endocrinology drugs, markets BTG's human growth hormone incorporating a novel, needle-free delivery system known as Medi-Jector rather than the traditional hypodermic needle hypodermic needle n. 1. A hollow needle used with a hypodermic syringe. 2. A hypodermic syringe including the needle. . "Children with growth retardation must take injections of the hormone almost daily, from age three through adolescence, so the ability to treat themselves without using a needle may greatly improve the quality of their lives," stated Mr. Chris Thomas, president of Ferring Germany. Sim Fass, president and chief executive officer of BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group , stated: "We welcome the wider distribution of our human growth hormone and look forward to additional launches of the product over the coming months. With the introductions in The United Kingdom, France and Spain, our human growth hormone has now been commercialized in four of the five key European markets. "The introduction in Germany took place earlier this year and the launch in Italy is slated to occur in the next few months. Sales in these countries will provide for continued product sales growth. We believe that Ferring will successfully capture meaningful market share. The use of Medi-Jector, the needle-free delivery system, should differentiate our growth hormone growth hormone or somatotropin (sōmăt'ətrō`pən), glycoprotein hormone released by the anterior pituitary gland that is necessary for normal skeletal growth in humans (see protein). from other competitive products." In addition to Europe, BTG's human growth hormone is currently marketed in Argentina, Israel, Japan, Mexico, the Philippines, South Korea, Thailand and Uruguay. Bio-Technology General Corp. develops, manufactures and markets genetically engineered and other products for human healthcare. CONTACT: Investor Relations Don Weinberger Leah Berkovits STRATEGIC GROWTH INTERNATIONAL BIO-TECHNOLOGY GENERAL CORP. 516-829-7111 908-632-8800 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion